Skip to main content
main-content

Latest news

Neuer Inhalt Free Registration

Gain full access to the latest clinical content available from Springer Nature

Breaking headlines, in-depth features, hot topic review articles, and 

the latest from major international conferences brought to you by


Editors' pick

11-12-2017 | Breast cancer | News

Contemporary hormonal contraceptives not free from breast cancer risk

A Danish population-based study shows that women who are current or recent users of contemporary hormonal contraceptives have an elevated risk for developing breast cancer relative to those who have never used such measures, but the absolute increase in risk remains small.

Source:

N Engl J Med 2017; 377: 2228–2239, 2276–2277

Latest headlines

15-12-2017 | Liver cancer | News

HBV remains major contributor to primary liver cancer globally

Hepatitis B virus infection is the leading cause of incident primary liver cancer and associated mortality worldwide, according to research published in JAMA Oncology.

Source:

JAMA Oncol 2017; 3: 1683–1691
Int J Infect Dis 2017; 65: 15–21

15-12-2017 | Prostate cancer | News

News in brief

Enzalutamide may not be contraindicated for mCRPC patients with seizure risk factors

In men with metastatic castration-resistant prostate cancer and seizure risk factors, treatment with enzalutamide does not increase the incidence of seizures, shows the UPWARD safety study.

14-12-2017 | Breast cancer | News

Short-term GnRHa therapy may prevent breast cancer chemotherapy-related ovarian dysfunction

Temporary ovarian suppression with a gonadotropin-releasing hormone analog alongside neoadjuvant or adjuvant chemotherapy could help preserve ovarian function and fertility in premenopausal women with early-stage breast cancer, shows a pooled analysis.

Source:

SABCS 2017; San Antonio, Texas, USA

13-12-2017 | Venous thromboembolism | News

Edoxaban matches dalteparin performance for cancer-associated VTE

The oral factor Xa inhibitor edoxaban is as good as subcutaneous dalteparin for the prevention of recurrent venous thromboembolism or major bleeding in patients with cancer, show results of the Hokusai VTE cancer trial.

Source:

N Engl J Med 2017; Advance online publication, ASH 2017; Atlanta, Georgia, USA

In depth

Bevacizumab in cervical cancer

The phase III GOG 240 trial evaluated bevacizumab in women with advanced cervical cancer - Advisory Board member and lead investigator Krishnansu Tewari outlines the results of the final analysis in this podcast.

21-04-2017 | Lymphoma | Feature | Article

Lymphoma in practice: Professor Anas Younes speaks to medwireNews

Professor Anas Younes tells medwireNews about the current issues in lymphoma practice, both for the clinician and patients.

01-02-2017 | Patient-reported outcomes | Feature | Article

The time is right for patient-reported outcomes

medwireNews talks to Professor Dame Lesley Fallowfield and Dr Ethan Basch about the barriers to the routine incorporation of patient-reported outcomes in oncology clinical trials, and the changes that are happening.

Calendar Upcoming events

Conference highlights

10-09-2017 | Collection

medwireNews@ESMO 2017

We provide the latest research news, interviews, and much more from the ESMO 2017 Congress, in Madrid, Spain.

04-06-2017 | Collection

medwireNews@ASCO 2017

We provide coverage from the annual meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, USA. Click through for news stories, conference reports, interviews and more.

03-02-2017 | Collection

medwireNews@ASH 2016

News from annual meeting of the American Society of Hematology, held in San Diego, California, USA. Click through to read the full reports.

image credits